6533b7dbfe1ef96bd12714db
RESEARCH PRODUCT
Leishmaniasis, autoimmune rheumatic disease, and anti–tumor necrosis factor therapy, Europe.
Ioannis D. XynosNikolaos V. SipsasDimitrios PikazisMaria G Tektonidousubject
MaleNecrosisgenetic structuresEpidemiologymedicine.medical_treatmentAnti-Inflammatory Agentslcsh:MedicineAnti-TNF0302 clinical medicineRisk FactorsMedicine030212 general & internal medicinerheumatic diseaseLeishmaniasisLeishmaniaimmunosuppressionbiologyDispatchAntibodies MonoclonalRheumatic diseaseImmunosuppressionMiddle Aged3. Good healthEuropeTreatment OutcomeInfectious DiseasesRheumatic feverFemaleTumor necrosis factor alphaImmunotherapymedicine.symptomMicrobiology (medical)medicine.medical_specialtytumor necrosis factor030231 tropical medicineletterparasiteslcsh:Infectious and parasitic diseases03 medical and health sciencesRheumatic DiseasesAnimalsHumansautoimmune diseaseslcsh:RC109-216Letters to the EditorAged030203 arthritis & rheumatologyTumor Necrosis Factor-alphabusiness.industryscreeninglcsh:RLeishmaniasisImmunotherapyLeishmaniabiology.organism_classificationmedicine.diseaseDermatologyInfliximabAnti-Tumor Necrosis Factor TherapyImmunologysense organsbusinessdescription
We report 2 cases of leishmaniasis in patients with autoimmune rheumatic diseases in Greece. To assess trends in leishmaniasis reporting in this patient population, we searched the literature for similar reports from Europe. Reports increased during 2004–2008, especially for patients treated with anti–tumor necrosis factor agents.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-10-01 | Emerging Infectious Diseases |